Table 3

Univariable mediation analysis of risk of CV death with empagliflozin versus placebo: time-dependent covariate analysis adjusting for the updated mean of each variable

HR for CV death with empagliflozin vs. placebo (95% CI)Percentage mediation
Unadjusted0.615 (0.491, 0.770)
Adjusted for
 HbA1c0.687 (0.543, 0.868)22.8
 FPG0.709 (0.559, 0.898)29.3
 SBP0.610 (0.485, 0.766)−1.7
 DBP0.618 (0.493, 0.774)1.0
 Heart rate0.623 (0.497, 0.782)2.7
 LDL-C0.591 (0.471, 0.741)−8.2
 HDL-C0.629 (0.500, 0.789)4.6
 logTG0.603 (0.481, 0.757)−4.1
 FFAs0.587 (0.463, 0.743)−9.6
 logUACR0.672 (0.536, 0.844)18.2
 eGFR (MDRD)0.601 (0.480, 0.752)−4.7
 eGFR (CKD-EPI)0.597 (0.477, 0.748)−6.1
 Weight0.588 (0.466, 0.741)−9.2
 BMI0.588 (0.466, 0.742)−9.2
 WC0.602 (0.480, 0.755)−4.4
 Hematocrit0.791 (0.620, 1.009)51.8
 Hemoglobin0.768 (0.604, 0.978)45.7
 Albumin0.717 (0.571, 0.900)31.6
 Uric acid0.673 (0.536, 0.845)18.5
  • Cox proportional hazards regression analysis in patients treated with one or more doses of study drug. FFA, free fatty acid; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; TG, triglyceride; WC, waist circumference.